- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
ZIM Laboratories, through its Australian subsidiary ZIMTAS, has secured Marketing Authorization from the Therapeutic Goods Administration for Rizatriptan Benzoate Orally Disintegrating Films in Australia. This product, designed for acute migraine treatment, offers a patient-friendly, water-free option, enabling rapid relief. This marks ZIM's inaugural Australian approval, signifying a crucial milestone for expanding its presence in regulated markets. The authorization is expected to facilitate commercial launch in Australia, serve as a springboard for further regulatory filings in the Asia-Pacific region, and validate ZIM's oral thin film technology as a globally relevant drug delivery platform.